Author:
Metsu David,Aquilina Christian,Delobel Pierre,Gandia Peggy,Savagner Frédérique,Raymond Stéphanie,Caron Philippe,Martin-Blondel Guillaume
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference27 articles.
1. The maraviroc expanded access program – safety and efficacy data from an open-label study;Lazzarin;HIV Clin Trials,2015
2. Safety, efficacy and indications of prescription of maraviroc in clinical practice: factors associated with clinical outcomes;Llibre;Antiviral Res,2015
3. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV 1;Fätkenheuer;Nat Med,2005
4. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection;Perry;Drugs,2010
5. Polypharmacy, drug–drug interactions, and inappropriate drugs: new challenges in the aging population with HIV;Courlet;Open Forum Infect Dis,2019